Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives $29.67 Average PT from Analysts

Shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) have been given a consensus recommendation of “Moderate Buy” by the six research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $29.6667.

TENX has been the topic of a number of research analyst reports. Cantor Fitzgerald assumed coverage on shares of Tenax Therapeutics in a report on Tuesday, March 17th. They set an “overweight” rating and a $35.00 price objective on the stock. Lifesci Capital raised shares of Tenax Therapeutics to a “strong-buy” rating in a report on Thursday, March 12th. William Blair reaffirmed an “outperform” rating on shares of Tenax Therapeutics in a report on Tuesday, March 10th. Finally, Guggenheim upped their price target on shares of Tenax Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a report on Monday, March 16th.

Institutional Trading of Tenax Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Boothbay Fund Management LLC purchased a new stake in shares of Tenax Therapeutics in the third quarter valued at about $2,680,000. Corient Private Wealth LLC purchased a new stake in shares of Tenax Therapeutics in the fourth quarter valued at about $151,000. Quadrature Capital Ltd purchased a new stake in shares of Tenax Therapeutics in the fourth quarter valued at about $252,000. Bridgeway Capital Management LLC purchased a new stake in shares of Tenax Therapeutics in the fourth quarter valued at about $547,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Tenax Therapeutics in the fourth quarter valued at about $273,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Trading Up 0.1%

TENX stock opened at $11.66 on Friday. The company has a market cap of $200.55 million, a P/E ratio of -8.77 and a beta of 1.00. Tenax Therapeutics has a 52 week low of $5.34 and a 52 week high of $18.38. The company’s 50-day moving average price is $13.80 and its 200 day moving average price is $11.98.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings data on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.88. On average, equities research analysts expect that Tenax Therapeutics will post -1.6 earnings per share for the current year.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.